Peter Keane

The study shows that RUNX1-ETO levels determine endothelial reprogramming and hematopoietic cell growth in AML by altering the balance between these processes.

This study shows a heterozygous CEBPA mutation in the bZIP domain causes MDS progression by altering chromatin structure and clonal composition, using patient-derived iPSCs.

The paper identifies critical transcription factor regulons in FLT3-ITD+ AML by analyzing gene regulatory networks and shows their necessity for AML growth.

The paper identifies chromatin priming elements that activate before gene expression during hematopoietic differentiation and shows their role in developmental timing.

The paper identifies thousands of cell stage-specific enhancers that drive hematopoietic specification by responding to cytokine signals and transcription factors.

The paper shows that different RUNX1 mutations alter gene regulatory networks and chromatin programming, leading to distinct hematopoietic differentiation trajectories and disease phenotypes.